Evidence map›Paper›PMID 40121387›Full record

ArticleJournal of neurology2025

Dyspnea and dystussia in Parkinson's disease: patient-reported prevalence and determinants.

Veerle A van de Wetering-van Dongen, Maarten J Nijkrake, Philip J van der Wees, Joanna IntHout, S K L Darweesh, Bastiaan R Bloem, Johanna G Kalf

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Veerle A van de Wetering-van DongenDepartment of Rehabilitation, Center of Expertise for Parkinson and Movement Disorders, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, 6500 HB, P.O. Box 9101 (internal code 898), Nijmegen, The Netherlands. veerle.vandewetering-vandongen@radboudumc.nl.ORCID http://orcid.org/0000-0003-4256-9265
Maarten J NijkrakeDepartment of Rehabilitation, Center of Expertise for Parkinson and Movement Disorders, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, 6500 HB, P.O. Box 9101 (internal code 898), Nijmegen, The Netherlands.
Philip J van der WeesDepartment of Rehabilitation and IQ Healthcare, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Joanna IntHoutDepartment for Health Evidence, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
S K L DarweeshDepartment of Neurology, Center of Expertise for Parkinson and Movement Disorders, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands.
Bastiaan R BloemDepartment of Neurology, Center of Expertise for Parkinson and Movement Disorders, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands.
Johanna G KalfDepartment of Rehabilitation, Center of Expertise for Parkinson and Movement Disorders, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, 6500 HB, P.O. Box 9101 (internal code 898), Nijmegen, The Netherlands.

Funding

Gatsby Foundation GAT3676
6 · The paper itself

Abstract

backgroundThe prevalence of respiratory dysfunction in PD is unknown and a better understanding of determinants contributing to respiratory dysfunction is important to facilitate early recognition and treatment.

objectiveTo examine the prevalence and determinants of self-reported symptoms of respiratory dysfunction among people with PD.

methodsIn a cross-sectional study, we administered a self-completed questionnaire among a sample of 939 persons with PD. Respiratory dysfunction was defined as experiencing at least one of the following symptoms: breathing difficulties, breathlessness/shortness of breath, tightening of the chest, frequent throat clearing, frequent coughing, or coughing difficulties. A principal component analysis (PCA) was used to define composite constructs of respiratory dysfunction. The association with participant-reported determinants was assessed using multivariable logistic regression models (with adjustment for pulmonary diseases and COVID-19 symptoms).

resultsThe overall prevalence rate of respiratory dysfunction was 44% in persons with PD (42% after excluding pulmonary diseases or COVID-19). The PCA resulted in two constructs of respiratory dysfunction: 'dyspnea' and 'dystussia' (an impaired cough response), which together explained 68% of the total variance. Female sex (OR = 1.39), higher BMI kg/m

conclusionsDyspnea and dystussia are common manifestations of respiratory dysfunction among people with PD and deserves more awareness in clinical practice. A proactive screening for the determinants of dyspnea and dystussia may contribute to earlier recognition and treatment of respiratory dysfunction.

Indexed as

DyspneaParkinson DiseaseAgedAged, 80 and overCoughCross-Sectional StudiesFemaleHumansMaleMiddle AgedPrevalenceSelf ReportBreathingDyspneaParkinson’s diseasePathophysiologyRespiratory dysfunctionScreening

Identifiers

PMID40121387
PMCPMC11929639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.